USFDA concludes inspection at Lupin’s Nagpur facility with no observations

14 May 2018 Evaluate

Lupin has successfully completed an inspection carried out by the US Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations. The company’s Nagpur facility is the latest facility and manufactures oral solid products.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2137.15 -27.90 (-1.29%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×